← Leaderboards
Ralf Paus
University Of Miami School Of Medicine
$785,012
Attributed
$1,701,586
Total exposure
2
Grants
1
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $732.4K · FY2022–25$1M$750K$500K$250K$0
'22
'23
'24
'25
Funding mix
By agency
NIH$1,701,586 · 2
By mechanism
R01$1,306,899 · 1
R21$394,687 · 1
Top collaborators
- Tongyu Cao Wikramanayake5 shared
- Xiangxi Mike Xu1 shared
Most similar at University Of Miami School Of Medicine
Same institution · by research overlap
- Oliver Gene McDonald$2,682,878
- Scheffer C G Tseng$11,372,554
- Xiangxi Mike Xu$16,938,053
Others in their field
Other Rising Stars on “Innovation”
- Rebecca Montalvan · Westat, Inc.$86,600,000
- Mari Ostendorf · University Of Washington$51,931,230
- Richard Smith · Medical Device Innovation Consortium$41,401,350
- Julia Louise Moore Vogel · Scripps Research Institute, The$32,252,685
- Christina Millin · Rho Federal Systems Division, Inc.$31,828,916
- Cyrus Wadia · Activate Global, Inc.$31,489,493
Research focus
InnovationOrgan Culture TechniquesSkinAlopeciaBiologyHairIn VivoScalp StructureCellsElementsElasticityDruggable TargetAcne VulgarisEndocrineFasn GeneDermalAdipokinesCritical PathwaysDermis3-DimensionalAntagonistClustered Regularly Interspaced Short Palindromic RepeatsAdipose TissueC-Myc Genes
Grant awards (5)
MPZL3 as a Therapeutically Targetable Mitochondrial Regulator of Sebaceous Gland Homeostasis and Sebum Production$303,930
R01 · FY2025 · AR
MPZL3 as a Therapeutically Targetable Mitochondrial Regulator of Sebaceous Gland Homeostasis and Sebum Production$327,569
R01 · FY2024 · AR
Pre-clinical testing of low intensity ultrasound as novel strategy to prevent paclitaxel-induced hair follicle damage in a humanized mouse model of chemotherapy-induced alopecia$394,687
R21 · FY2023 · CA · contact PI
MPZL3 as a Therapeutically Targetable Mitochondrial Regulator of Sebaceous Gland Homeostasis and Sebum Production$337,700
R01 · FY2023 · AR
MPZL3 as a Therapeutically Targetable Mitochondrial Regulator of Sebaceous Gland Homeostasis and Sebum Production$337,700
R01 · FY2022 · AR